The Global Economic Cost of Cancer—Estimating It Is Just the First Step!
Menée dans 204 pays et territoires, cette étude présente une estimation, pour la période 2020-2050, des coûts associés à 29 types de cancer
In this issue of JAMA Oncology, Chen and colleagues estimate the global economic cost of the most prevalent cancers in 204 jurisdictions around the world for the 3-decade period starting in 2020. They appropriately used a macroeconomic framework, incorporating economic feedback and taking in consideration health as a factor affecting workers and investment. They estimated that cancer will cost the world $25.2 trillion (at 2017 international prices) between 2020 and 2050, which corresponds to 0.55% of annual global gross domestic product. This cost is skewed toward high-income nations, despite three-quarters of deaths occurring in low- and middle-income countries. In this editorial, we will review the background to their study, their assumptions, and the appropriateness of their model. Most importantly, we will also discuss the implications of their findings in terms of how the human and economic burden of cancer can be addressed.
JAMA Oncology , éditorial, 2022